Brief: Actinogen Commences Open-Label Phase Of Xanamia Alzheimer’S Trial And Provides Business Update
01/04/2026 14:12
April 1 (Reuters) - Actinogen Medical Ltd ACW.AX: ACTINOGEN COMMENCES OPEN-LABEL PHASE OF XANAMIA ALZHEIMER’S TRIAL AND PROVIDES BUSINESS UPDATE ACTINOGEN MEDICAL: IN CURRENT QUARTER, CO PLANS TO MEET WITH EMA TO DISCUSS OPPORTUNITIES TO STREAMLINE PATHWAY TO XANAMEM APPROVAL IN EUROPEAN UNION Source text: ID:nGNX5brQjR Further company coverage: ACW.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinogen Medical
See all newsBrief: Actinogen Commences Open-Label Phase Of Xanamia Alzheimer’S Trial And Provides Business Update
Brief: Actinogen Medical Completes A$16.8M Placement And Spp
Brief: Actinogen Medical To Raise A$12.0 Million
Brief: Actinogen Medical Seeks Trading Halt
Brief: Actinogen Randomizes 247th Patient in Xanamia Phase 2b/3 Alzheimer’s Trial